US Judge Ruling for FDA Bars Copies of Lilly Weight Loss Drug
A U.S. federal judge has denied an injunction that would have allowed compounding pharmacies to keep making copies of Eli Lilly's popular weight-loss drug Zepbound in the U.S. The decision was filed late on Wednesday in response to an October lawsuit from a compounding industry group against the U.
Eli Lilly and Co. is in negotiations with several states and plans to announce the locations of four new manufacturing plants ...
Eli Lilly plans to spend $27 billion to build new drug manufacturing sites in the U.S., at a time when President Trump is ...
Pharmaceutical giant expects the move will create 3,000 high-skilled jobs and provide work for approximately 10,000 ...
Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional ...
A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...
The partnership comes as telehealth companies grapple with restrictions on the sale of some compounded GLP-1s.
The weight-loss drug market is evolving at a rapid speed, with leading pharma companies including Novo Nordisk and Eli Lilly ...
In this week’s edition of InnovationRx, we look at Eli Lilly’s weight-loss pill stockpiling, scaling stem cell manufacturing, ...
Eli Lilly announced plans for four new pharmaceutical manufacturing sites to produce domestic medicine production in the ...
Late-breaking results from Eli Lilly and Company (NYSE: LLY) and Incyte (NASDAQ: INCY) found adolescent patients (ages 12 to under 18) with severe alopecia areata (AA) treated with once-daily ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback